Summary of Use during Lactation

No information is available on the clinical use of ribociclib during breastfeeding. Because protein binding of ribociclib is 70%, clinically important amounts of the drug might pass into breastmilk. The manufacturer recommends that breastfeeding be discontinued during ribociclib therapy and for at least 3 weeks after the final dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Ribociclib

CAS Registry Number

1211441-98-3

Drug Class

• Breast Feeding
• Lactation
• Antineoplastic Agents
• Enzyme Inhibitors
• Protein Kinase Inhibitors
• Signal Transduction Inhibitors